Literature DB >> 18669085

[Character of refractive errors in population study performed by the Area Military Medical Commission in Lodz].

Michał S Nowak1, Roman Goś, Janusz Smigielski.   

Abstract

PURPOSE: To determine the prevalence of refractive errors in population.
MATERIAL AND METHODS: A retrospective review of medical examinations for entry to the military service from The Area Military Medical Commission in Lodz. Ophthalmic examinations were performed. We used statistic analysis to review the results.
RESULTS: Statistic analysis revealed that refractive errors occurred in 21.68% of the population. The most commen refractive error was myopia.
CONCLUSIONS: 1) The most commen ocular diseases are refractive errors, especially myopia (21.68% in total). 2) Refractive surgery and contact lenses should be allowed as the possible correction of refractive errors for military service.

Entities:  

Mesh:

Year:  2008        PMID: 18669085

Source DB:  PubMed          Journal:  Klin Oczna        ISSN: 0023-2157


  2 in total

1.  No Evidence for Association of SCO2 Heterozygosity with High-Grade Myopia or Other Diseases with Possible Mitochondrial Dysfunction.

Authors:  Dorota Piekutowska-Abramczuk; Beata Kocyła-Karczmarewicz; Maja Małkowska; Sylwia Łuczak; Katarzyna Iwanicka-Pronicka; Stephanie Siegmund; Hua Yang; Quan Wen; Quan V Hoang; Ronald H Silverman; Paweł Kowalski; Olga Szczypińska; Kamila Czornak; Janusz Zimowski; Rafał Płoski; Jacek Pilch; Elżbieta Ciara; Jacek Zaremba; Małgorzata Krajewska-Walasek; Eric A Schon; Ewa Pronicka
Journal:  JIMD Rep       Date:  2015-10-02

2.  Axial length and its associations in a Russian population: The Ural Eye and Medical Study.

Authors:  Mukharram M Bikbov; Gyulli M Kazakbaeva; Timur R Gilmanshin; Rinat M Zainullin; Inga I Arslangareeva; Venera F Salavatova; Guzel M Bikbova; Songhomitra Panda-Jonas; Nikolai A Nikitin; Artur F Zaynetdinov; Ildar F Nuriev; Renat I Khikmatullin; Yulia V Uzianbaeva; Dilya F Yakupova; Said K Aminev; Jost B Jonas
Journal:  PLoS One       Date:  2019-02-01       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.